Company: SION
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0002036042-25-000016
Chunk: 460

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 2
Chunk 460
---
 our operations, which we may obtain from additional equity or debt financings or strategic agreements.

As of March 31, 2025, we had $354.7 million in cash, cash equivalents and marketable securities.

Cash Flows

The following table sets forth a summary of the net cash flow activity (in thousands):

Three Months Ended March 31,20252024Net cash used in operating activities$(16,288)$(13,175)Net cash used in investing activities(141,194)(123,927)Net cash provided by financing activities202,389 181,333 Net increase in cash, cash equivalents and restricted cash$44,907 $44,231 

20

Table of Contents

Operating Activities

For the three months ended March 31, 2025, net cash used in operating activities was $16.3 million primarily due to our net loss of $16.5 million and changes in operating assets and liabilities of $1.9 million, partially offset by $2.0 million of net non-cash charges, which includes stock-based compensation, depreciation, non-cash operating lease expense and amortization of discounts on marketable securities.

For the three months ended March 31, 2024, net cash used in operating activities was $13.2 million  primarily due to our net loss of $11.8 million and changes in operating assets and liabilities of $2.5 million, partially offset by $1.2 million of net non-cash charges, which includes stock-based compensation, depreciation, non-cash operating lease expense and amortization of discounts on marketable securities.

Investing Activities

Net cash used in investing activities was $141.2 million during the three months ended March 31, 2025, which was primarily driven by purchases of marketable securities of $171.6 million, partially offset by maturities of marketable securities of $30.5 million.

Net cash used in investing activities was $123.9 million during the three months ended March 31, 2024, due to purchases of marketable securities.

Financing Activities

Net cash provided by financing activities was $202.4 million during the three months ended March 31, 2025, as compared to $181.3 million during the three months ended March 31, 2024. During the three months ended March 31, 2025, and 2024, the Company closed its IPO and Series C Financing, respectively. 

Future Funding Requirements